De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers vooraf aan de titels van de abstracten deze vinden.
Aanbevolen abstracten door Dr. Jean-Yves Douillard:
Friday, October 20, 2023
14:00–15:45 CEST; Proffered Paper Session
Non-Metastatic NSCLC and Other Thoracic Malignancies
LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JD Spicer
1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. MM Awad
Friday, October 20, 2023
16:00–17:30 CEST; Proffered Paper Session
NSCLC, Metastatic
LBA63 SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC). H Borghaei
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. MC Garassino
Saturday, October 21, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 1
LBA1 CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC. T Cascone
LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). BJ Solomon
LBA4 Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC. HHF Loong
LBA5 Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study. N Girard
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3
LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01. AE Lisberg
LBA14 Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial. BC Cho
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "ESMO 2023: aanbevolen abstracten van studies bij longkanker door oncologen en medisch specialisten"